Charles River Now Offers MucilAir™ Human Airway Toxicity Test
April 24, 2012 - MucilAir™ was evaluated for use in predicting upper airway toxicity by treating tissues with increasing concentrations of sodium dodecyl sulfate (SDS). Evaluations were performed to assess monolayer integrity (transepithelial electrical resistance [TEER]), membrane integrity (lactate dehydrogenase [LDH] release), metabolic competence (resazurin metabolism) and inflammatory mediator (IL-8) release. Histology and scanning electron microscopy (SEM) were used to assess morphology.
Scanning electron micrograph of MucilAir® (x6400)
When treated with SDS, it was concluded that MucilAir™ displayed dose-dependent responses, with cytotoxicity visualized by histology at ≥0.6 mM and measured chemically at ≥1.25 mM. Monolayer integrity (TEER) and marker release (LDH and IL-8) patterns were comparable between equivalently dosed units. These data support the use of MucilAir™ as a relevant model for airway toxicity studies.
For more information, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.
Related Info
- Poster: MucilAir™, an In Vitro Model for Assessment of Human Airway Toxicity, Evaluated Using Model Irritant Sodium Dodecyl Sulfate (SDS) (Available in The Source℠. Click here to log in or click here to register.)
- Podcast: Evaluation of MucilAir™ as an In Vitro Model of Human Airway Epithelium (Available in The Source℠. Click here to log in or click here to register.)